We demonstrate that multiple promoters and alternate splicing regulate expression of the human CRH receptor type 2 (CRHR2) gene. We show that flanking regions to the first exons drive promoter activity in both endogenously and nonendogenously expressing cell lines. Putative promoter elements have been identified that are conserved between species, including the comparison of CRHR2 ␥ in nonhuman primates that was previously known only in humans, which may be responsible for subtype tissue specific regulation. We have identified novel transcripts produced by alternate splicing of the first exon of CRHR2 ␤ (␤1a) with various combinations of the 5 exons including a novel exon (␤1c) spliced to the common exons. C RH IS A 41-AMINO-ACID peptide (1) that plays a key role in the integration of the neuroendocrine, behavioral, autonomic, and immune responses to stress (2). The primary role of CRH is to activate the proopiomelanocortin gene and generate the release of ACTH and ␤-endorphin from the anterior pituitary (3). In addition, CRH has been shown to improve arousal and learning, cause anxiety, modulate food intake, disrupt sleep patterns, stimulate thermogenesis, alter blood pressure, and exert both antiinflamatory and proinflammatory effects (4, 5). This is coordinated by the expression of two receptors, CRH receptor type 1 (CRHR1) (6) and type 2 (CRHR2) (7) encoded by separate genes mapped to human chromosome 17 (8) and 7 (9), respectively. These receptors belong to the group II subfamily of G protein-coupled receptors (GPCRs), a distinct family of seven transmembrane spanning receptors, which includes among others, receptors for calcitonin, vasoactive intestinal peptide, and PTH. The CRHR1 binds CRH and CRH-related peptides (urocortin, urotensin, and sauvagine) with high affinity. The CRHR2 receptor binds urocortin with higher affinity than the other CRH-like peptides (10) and also binds the newly identified stresscopin and stresscopin-related peptides (11), suggesting that these peptides are the natural or preferred ligands. CRHR1 shares 70% homology with CRHR2 and both CRH receptors are present as structurally distinct isoforms. The CRHR1 gene expresses four known subtypes (1 ␣ , 1 ␤ , 1 c , and 1 d ; Refs. 6, 12, and 13) produced by differential splicing of exons 3, 6, and 13. CRHR1 is abundantly expressed in the brain and pituitary (14) but also at low levels in the testis, ovary, and adrenals (15-17). The CRHR2 gene expresses three known subtypes (2 ␤ , 2 ␥ , and 2 ␣ ; Refs. [18] [19] [20] that are produced by the use of alternate 5Ј exons. The CRHR2 ␣ and the CRHR2 ␤ are expressed in both the brain and periphery (21), although CRHR2 ␣ is mainly localized to the subcortical structures (21), whereas the CRHR2 ␥ appears to be predominantly in the brain (22). In addition, both the CRHR2 ␣ and CRHR2 ␤ subtypes are differentially expressed in heart, skeletal muscle, and myometrium (18, 23) .
C RH IS A 41-AMINO-ACID peptide (1) that plays a key role in the integration of the neuroendocrine, behavioral, autonomic, and immune responses to stress (2) . The primary role of CRH is to activate the proopiomelanocortin gene and generate the release of ACTH and ␤-endorphin from the anterior pituitary (3) . In addition, CRH has been shown to improve arousal and learning, cause anxiety, modulate food intake, disrupt sleep patterns, stimulate thermogenesis, alter blood pressure, and exert both antiinflamatory and proinflammatory effects (4, 5) . This is coordinated by the expression of two receptors, CRH receptor type 1 (CRHR1) (6) and type 2 (CRHR2) (7) encoded by separate genes mapped to human chromosome 17 (8) and 7 (9) , respectively. These receptors belong to the group II subfamily of G protein-coupled receptors (GPCRs), a distinct family of seven transmembrane spanning receptors, which includes among others, receptors for calcitonin, vasoactive intestinal peptide, and PTH. The CRHR1 binds CRH and CRH-related peptides (urocortin, urotensin, and sauvagine) with high affinity. The CRHR2 receptor binds urocortin with higher affinity than the other CRH-like peptides (10) and also binds the newly identified stresscopin and stresscopin-related peptides (11) , suggesting that these peptides are the natural or preferred ligands. CRHR1 shares 70% homology with CRHR2 and both CRH receptors are present as structurally distinct isoforms. The CRHR1 gene expresses four known subtypes (1 ␣ , 1 ␤ , 1 c , and 1 d ; Refs. 6, 12, and 13) produced by differential splicing of exons 3, 6, and 13. CRHR1 is abundantly expressed in the brain and pituitary (14) but also at low levels in the testis, ovary, and adrenals (15) (16) (17) . The CRHR2 gene expresses three known subtypes (2 ␤ , 2 ␥ , and 2 ␣ ; Refs. [18] [19] [20] that are produced by the use of alternate 5Ј exons. The CRHR2 ␣ and the CRHR2 ␤ are expressed in both the brain and periphery (21) , although CRHR2 ␣ is mainly localized to the subcortical structures (21) , whereas the CRHR2 ␥ appears to be predominantly in the brain (22) . In addition, both the CRHR2 ␣ and CRHR2 ␤ subtypes are differentially expressed in heart, skeletal muscle, and myometrium (18, 23) .
Targeted disruption of CRH receptors in mice has provided insights into the importance of the different CRH receptors. These studies have implicated CRHR1 in mediating normal responses to stress (24) , whereas CRHR2 appears to play important roles in fine tuning stress responses (25) . Furthermore, CRHR1 mediates anxiogenic actions that are opposed by the anxiolytic properties of CRHR2 (26) . In addition, CRHR2 mediates the haemodynamic effects of urocortin (27) . The different distribution and pharmacology of the receptor subtypes suggests that they sub-serve different physiological roles. The understanding of the mechanisms involved in CRHR2 expression at transcriptional and translational levels and the physiological role of the CRHR2 gene would be facilitated greatly by elucidation of the structure and processing of its gene. Our studies present the characterization of the structure and function of the 5Ј region of the human CRHR2 gene and describe mechanisms regulating receptor subtype expression.
RESULTS

Isolation and Structural Organization of the Human CRHR2 Gene
Genomic library screening yielded one positive plaque containing a 40-kb clone Jp1. Restriction digested fragments of Jp1 were analyzed by Southern blot and sequencing of these fragments revealed the organization of the 5Ј exons of the CRHR2 gene (Fig. 1) . Fragments Jp1-SstI (4.1 kb) and Jp1-SstI/SphI (3.0 kb) both contained the CRHR2 ␣ unique exon and the first common exon, these were separated by an intronic sequence of 137 bp. DNA fragment Jp1-SphI (3.2 kb), which overlapped with JpI-SstI (4.1 kb), contained the CRHR2 ␥ unique exon, which was separated from the CRHR2 ␣ exon by an intron of 4056 bp. A final fragment Jp1-NdeI (8.0 kb) contained the CRHR2 ␥ exon and 94 bp of CRHR2 ␤ (␤1b) separated by an intron of 2575 bp. This suggested that the unique amino terminus of CRHR2 ␤ results from fusion of two unique exons. Attempts to amplify the region between these two exons using NcoI digested-polyadenylated genomic DNA, were unsuccessful suggesting that the two exons were interrupted by a large intron. Comparison of the above sequences and cDNA sequences for CRHR2 revealed 100% homology with that of human PAC clone DJ1143H19 (accession no. AC004976). Sequence analysis of this genomic clone enabled us to complete the structural organization of the CRHR2 gene and complete the exon arrangement for each CRHR2 subtype (Fig. 2) . This revealed that CRHR2 ␤ contained two unique exons separated by a large 10,659-bp intron (Table 1) .
Characterization of 5-Untranslated Regions (UTRs) of the CRHR2 Subtypes
5Ј-Rapid amplification of 5Ј-cDNA ends (RACE) experiments using CRHR2 ␣ specific primers identified two transcripts (Fig. 3A) . The lower band contained the two unique CRHR2 ␤ exons (exons ␤1a and ␤1b) and the unique CRHR2 ␣ exon (exon ␣1). The upper band contained exons ␤1a and ␤1b, the unique CRHR2 ␥ exon (exon ␥1) and exon ␣1 (Fig. 3B ). This also extended the 5Ј-UTR of the CRHR2 ␣ gene by 52 nucleotides to a consensus 3Ј acceptor splice site used by the upstream exons. The average length of the 5Ј-UTR in eukaryotes is approximately 150 nucleotides (28) , which suggested that the transcription start site for CRHR2 ␣ was further upstream. We therefore compared the rat CRHR2 ␣ 5Ј-UTR sequence (7) with mouse, rat, and human genomic sequences containing the CRHR2 ␣ unique exon and 5Ј flanking sequences. The homology shared between these species in the 5Ј-UTR is over 60% and extends for over 200 nucleotides (Fig. 3C) . Transcription start site prediction programs using 1500 bp of human, rat, and mouse CRHR2 ␣ genomic sequence upstream of the start codon, indicated transcription initiation in proximity (1-46 nucleotides) from the end of the known 5Ј-UTR of the rat. This suggested that the 5Ј-UTR in all three species are similar in length, approximately 225 bp, but more importantly extends approximately 150 bp 5Ј to the 3Ј acceptor site. To verify that the 5Ј-UTR extends beyond the 3Ј acceptor site, CRHR2 ␣ was amplified by RT-PCR from human brain cDNA using a 5Ј primer (␣-207) located close to the predicted transcription start sites. Amplification of CRHR2 ␣ clearly indicated that the transcription start site is upstream of the 3Ј acceptor site and the 5Ј-UTR is over 207 bp (Fig. 3D) .
Using CRHR2 ␥ specific primers we identified two transcripts (Fig. 4A) , the lower band containing exons ␤1a, ␤1b, and ␥1 and the upper band exons ␤1a and ␤1b together with a 195-bp intronic sequence (␤1c) and exon ␥1 (Fig. 4B) . The 5Ј-UTR was extended by 15 nucleotides and, like CRHR2 ␣ , contained a consensus 3Ј splice site. The CRHR2 ␥ subtype was previously known only in humans. We have identified genomic clones from the GenBank database containing the CRHR2 ␥ subtype in olive baboon and chimpanzee. These species share over 85% homology to humans in their 5Ј sequence from the ATG for over 300 bp. The 3Ј acceptor splice site is highly conserved between species despite an insertion in the olive baboon and the predicted transcription start site is located upstream of the splice site at the same nucleotide in all species (Fig. 4C) . We identified two products using the CRHR2 ␤ -specific primer. The largest extended the 5Ј-UTR by 176 nucleotides to 226 bp, although the shorter fragment with a 5Ј-UTR of 201 bp was the major product (Fig. 5) .
Analysis of Promoter Activity Upstream of the Unique Exons for the CRHR2 Subtypes
The promoter activity of the sequence 5Ј to the unique CRHR2 ␤, ␥, and ␣ exons was studied by transient The sequences of exon-intron junctions are indicated. Exon and intron sequences are in capital and lowercase letters, respectively. Unique exons for each receptor ␤, ␥, and ␣ are indicated. expression assay with the luciferase gene as a reporter, in several cell lines. By using a dual luciferase assay, differences in transfection efficiencies were corrected for and activity was measured as a ratio of the two luciferases. Reporter assays with the largest construct for each subtype in four different cell lines indicated all constructs possessed promoter activity. This activity increased 10-fold in endogenously expressing cell lines (Fig. 6) . Analysis of the CRHR2 ␤ promoter sequence suggested the minimal promoter is contained between nucleotides Ϫ304 and Ϫ251 (Fig. 7A) . Analysis of the CRHR2 ␥ promoter sequence indicated that the minimal promoter to be within Ϫ237 nucleotides, but the putative TATA box was nonfunctional because mutating this element to TCTAC (pTATAmut) had no effect on promoter activity (Fig. 7B) . Analysis of the CRHR2 ␣ promoter sequence suggested that the minimal promoter is contained between nucleotides Ϫ350 and Ϫ250 (Fig. 7C) . This region is GC rich and contains multiple putative Sp1 elements that are also conserved within the same region on the mouse and rat CRHR2 ␣ promoters.
Sequence Analysis of the CRHR2 Promoters
Figures 8-10 show the sequence 5Ј to the unique exons for the CRHR2 ␣, ␥, and ␤. There is no typical TATA or CCAAT sequence in the promoter region of CRHR2 ␤ but several Sp1 binding elements (Fig. 8) . Several putative transcription factor elements were identified, myogenic MEF-2 at Ϫ195, E box elements at Ϫ349 and Ϫ217 capable of binding E12, MyoD, and myogenin. Elements for the ubiquitous and highly ex- Constructs containing the largest 5Ј sequences were transfected into four cell lines. CRHR2␣ is endogenously expressed in myometrial cells and A431 cells. Luciferase reporter constructs are labeled according to 5Ј flanking sequences from the ATG start codon. Luciferase reporter activity is derived from the mean relative luciferase activity from three experiments ϮSD.
pressed in brain Egr-1 factor (29) was identified at Ϫ168, and two elements for retinoid X receptor at Ϫ2479 and Ϫ1393. Comparative promoter analysis of the CRHR2 ␤ promoter with genomic sequences from chimpanzee, baboon, pig, bovine, cat, rat, and mouse (accession nos. AC091720, AC091714, AC091723, AC092193, AC091797, AC091712, and AC079243, respectively) indicated the region Ϫ1 to Ϫ200 to be highly conserved containing Sp1 elements and the myocyte specific enhancer MEF-2. The promoter region of CRHR2 ␥ contains a consensus TATA box element at Ϫ214, although this was shown to be non- Luciferase reporter constructs are labeled according to 5Ј flanking sequences from the ATG start codon. Luciferase reporter activity after transfection in four cell lines are derived from the mean relative luciferase activity from three experiments ϮSD. A, CRHR2 ␤ . B, CRHR2 ␥ . Construct p-TATAmut is identical to construct p-TATAnorm except for two mutations where A residues were switched to C residues producing a nonfunctional TATA box element. Luciferase activity is identical in these two constructs indicating the TATA box is nonfunctional. C, CRHR2 ␣ . functional in the reporter assays (Fig. 9) . Other elements present are Oct-1 at Ϫ278, Ϫ361 and Ϫ1161, CCAAT/enhancer binding protein at Ϫ358, Ϫ568, Ϫ639, Ϫ1158, estrogen receptor at Ϫ835, glucocorticoid receptor (GR) at Ϫ1698 and Pit-1a at Ϫ303, a pituitary transcription factor (30). Comparative promoter analysis of the CRHR2 ␥ with genomic sequences from chimpanzee and baboon indicated many elements to be conserved including those for estrogen receptor, GR, and Pit-1a. Genomic sequences from pig, bovine, cat, rat, and mouse between the CRHR2 ␤ and CRHR2 ␣ failed to identify CRHR 2␥ suggesting it is absent in these species. The CRHR2 ␣ promoter does not contain either a typical TATA or CCAAT motif. However, it is very GC rich and possesses several Sp1 binding elements upstream from the transcription start site (Fig. 10) . Other elements present include those for the ubiquitous serum response factor at Ϫ326, Ap-2 at Ϫ400 and Ϫ1132, nuclear factor-B at Ϫ1036, YY1 at Ϫ1140, progesterone receptor at Ϫ2756 and Ϫ2344, GR at Ϫ2755 and Ϫ2243, upstream stimulating factor at Ϫ1471 and the myogenic factor MRF4 at Ϫ1101. Comparative promoter analysis of the CRHR2 ␣ promoter with genomic sequences from chimpanzee, baboon, pig, bovine, cat, rat, and mouse indicated certain elements are conserved especially the Sp1 sites around the transcription start site but also those for GR and progesterone receptor (Fig. 10) .
DISCUSSION
We present the 5Ј structural organization of the human CRHR2 gene and demonstrate that it is regulated by multiple promoters and differential splicing. The human CRHR2 gene expresses three different subtypes, which are structurally distinct in their N-terminal extracellular domains and exhibit significant differences in their tissue distribution. The human CRHR2 gene spans 50 kb and consists of 15 exons. Exon ␤1a contains the 5Ј-UTR and start codon for CRHR2 ␤ and together with exon ␤1b, contributes to the N-terminal extracellular domain. Exons ␥1 and ␣1 contain the 5Ј-UTR and start codon for CRHR2 ␥ and CRHR2 ␣ , respectively, which contributes to their unique Nterminal extracellular domain. Exons 2-12 code for the remainder of the N-terminal domain, the seven transmembrane domains (exons 7-11), and the C-terminal intracellular domain, which are common to all CRHR2 receptors. The group II members of the GPCR family are unique in this respect as the rest of the GPCR family are predominantly intronless, especially within the protein coding region (reviewed in Ref. 31 ). The exon-intron organization of group II GPCRs suggests a common evolutionary origin and unlike other GPCR subfamilies permits extensive alternate splicing. This has allowed the potential for members to produce diverse receptors with alternate domains, which in turn produce receptors with differing ligand specificity, binding, and G protein coupling.
Luciferase reporter plasmids containing the 5Ј flanking regions of exons ␤1a, ␥1, and ␣1 induced similar and significant levels of activity, indicating the presence of three functional promoters. Gene regulation by use of multiple promoters is well described (32) especially in genes that direct the expression of mRNAs with alternate 5Ј-UTRs. For example, the ␥-glutamyltransferase gene and the GH receptor gene, which direct expression of six and eight mRNAs respectively, with different 5Ј-UTRs by the use of five intronic promoters (33, 34) . There are fewer examples of genes that use multiple promoters to express mRNAs that code for alternate N-terminal domains. The human phosphodiesterase 5A gene (35) and several PAR domain transcription factor genes each produce two such mRNAs by this mechanism (36-39). The emergence of multiple promoter regions has evolved to achieve differential and temporal expression of a gene with a specific capacity to respond to particular cellular or metabolic conditions. The 5Ј-flanking region of the CRHR2 ␤ , CRHR2 ␥ , and CRHR2 ␣ lack a functional TATA or CCAAT box, which is a feature typical of housekeeping genes. Heterogeneity of transcription initiation sites is also a common phenomenon in housekeeping genes, found associated with GC boxes. This is the case for the CRHR2 ␤ promoter and is likely to be the case for the CRHR2 ␣ promoter. The CRHR2 ␣ promoter is GC rich and contains several Sp1 binding elements, which suggests these elements constitute the minimal promoter. There are many potential upstream regulatory elements in the 5Ј flanking regions although there are several notable features. The CRHR2 ␤ and CRHR2 ␣ are expressed in heart, myometrium, and skeletal muscle and contain elements for myogenic transcription factors, whereas CRHR2 ␥ , which appears to be predominantly in the brain, contains none. CRHR2 has been demonstrated to be expressed in the pituitary, though the isoform has not been determined (40) . CRHR2 ␥ may possibly be the isoform expressed here as it contains an element for the pituitary specific factor Pit-1a. Comparative promoter analysis from genomic clones containing the CRHR2 gene from six other species (chimpanzee, baboon, bovine, pig, cat, mouse, and rat) indicate that the myocyte specific enhancer MEF-2 (41) in CRHR2 ␤ , the Sp1-rich region in CRHR2 ␣ and the pituitary specific element Pit-1a are conserved in all species. The highly conserved myocyte specific enhancer in the CRHR2 ␤ promoter may play an important role in regulating expression in the heart where urocortin, the preferred ligand of this subtype is also expressed. Comparative promoter analysis also revealed a common presence of steroid response elements, for progesterone, estrogen, glucocorticoids, and retinoic acid in all receptor subtypes. CRHR2 has shown to be regulated in the heart and brain by glucocorticoids (42, 43) . Putative glucocorticoid-responsive elements are present in CRHR2 ␣ , and some of these elements are highly conserved between species. Clearly, further analysis of the promoter sequences to establish which transcription factors are involved will reveal the mechanism of tissue specific regulation.
Identification of full-length 5Ј-UTR using hippocampus cDNA revealed two transcripts with a 5Ј-UTR of 201 bp and 226 bp for the CRHR2 ␤ , suggesting alternate transcriptional start sites. Identification of fulllength 5Ј-UTR for the CRHR2 ␥ and CRHR2 ␣ were unsuccessful as only alternate splice forms containing ␤ exons were amplified. We have attempted to identify the transcriptional start sites by ribonuclease protection assay and primer extension, but both were unsuccessful. This may be due to the low expression of these transcripts (detection of CRHR2 ␣ by PCR requires 35-40 cycles) but also that the size of the product for CRHR2 ␥ may be too small for these assays. The distance from the splice site to the transcriptional start site (which encompasses the CRHR2 ␥ unique sequence) may be only from 60-20 bp. Alternate splice forms of CRHR2 have been reported previously (18) , which contain exons ␤1a-2 and ␤1a-1b-␥1-2 (Figs. 5 and 4, respectively). We identified three novel alternate splice forms that were highly expressed (Figs. 3B and  4B ). This suggests that CRHR2 ␤ pre-mRNA is differentially spliced producing five alternate splice forms, although if any permutation of exons between ␤1a and 2 occurs at least 12 alternate splice forms could be produced. Indeed, we consistently detected several fainter bands that we were unable to isolate. Sequencing of the 5Ј-RACE products extended the known 5Ј-UTR of CRHR2 ␥ and CRHR2 ␣ and revealed a consensus 3Ј splice site to which 5Ј exons are spliced. As we did not detect CRHR2 ␥ or CRHR2 ␣ transcripts with 5Ј-UTR extending beyond the 3Ј splice site, it suggests that they are not, or are only weakly expressed relative to alternate transcripts in the hippocampus. This emphasizes the problem of determining expression of functional CRHR2 subtypes in different tissues especially CRHR2 ␥ and CRHR2 ␣ when alternate splice forms are present and more highly expressed. Primers designed to the published unique sequences for CRHR2 ␥ and CRHR2 ␣ are unable to distinguish between functional transcripts and alternately spliced transcripts producing data that do not relate to the presence or quantity of functional receptor subtype (18, 22, 44, 45) . Therefore, primers or probes need to be designed to sequences upstream of the 3Ј acceptor splice sites that contain sequences unique to these subtypes. The 5Ј-UTR of the human CRHR2 ␣ shows high homology to that of the rat CRHR2 ␣ in which the 5Ј-UTR has been shown to extend beyond the 3Ј acceptor splice site for a further 163 nucleotides. We have determined the structure of the mouse CRHR2 ␣ gene by analysis of the mouse genome database (data not shown) and compared the predicted transcriptional start sites of both mouse and human to show they are similar to that of the rat. This was shown experimentally by amplifying the human CRHR2 ␣ with a primer upstream of the 3Ј acceptor splice site, using cDNA from both brain and myometrium, this extended the 5Ј-UTR to 207 nucleotides.
An increasing number of GPCR subtypes are expressed in the form of spliced variants with variable parts of the amino acid sequence modified (reviewed in Ref. 46 ). Most of these variant isoforms such as the somatostatin receptor 2b subtype (47) remain functional by keeping the basic seven transmembrane domains structures of the receptor molecule intact that are necessary for receptor activity. The physiological and pharmacological relevance of these splice variants depends on where alterations are situated. The largest number of splice variants are situated at the C terminus, e.g. the ␤-adrenoceptor variant B 1S (48) . Variants in the N terminus and the putative cytoplasmic loops are also relatively numerous, e.g. CRHR2 variants 2 ␤ , 2 ␥ , and 2 ␣ and the dopamine variant D 2S (49) , respectively. Splice variants in the putative extracellular loops or TMs are less frequent, e.g. the orphanin receptor variant OFQ 1E (50) and PAC receptor variant PAC 1TM4 (51), respectively. By contrast, there are reports of an increasing number of aberrant or truncated variants that have lost their ability to bind the natural ligand either because they have lost typical transmembrane-spanning domains as described for the nonfunctional dopamine D3 receptor (52) or because several transmembrane-spanning domains have been deleted. As observed for variants of the human GHRH receptor (53) , and the CRHR2 ␤ variants (18), which have the introduction of premature stop codons. Some of these aberrant forms are reported to be present in a tissue-specific manner as demonstrated by the neurotensin receptor (54), the rat CRHR2 ␣ receptor variants, which are differentially expressed in specific regions of the brain (55) , and CRHR1 receptor variants in the skin (56) . These variant forms are also conserved between species. An example of this is the short nonfunctional variant of the 5-hydroxy-tryptamine 2c receptor, which is produced by alternate splicing in rat, mouse, and human brain (57) . The variant receptor can be transiently expressed but has not been detected in vivo suggesting that it may be conserved due to regulation at the level of pre-mRNA processing rather than at the metabolic level. To our knowledge, none of the aberrant or truncated forms reported are expressed in vivo, suggesting that they may play a regulatory role not at the physiological level but at the level of transcript processing. Regardless of whether or not these aberrant transcripts are significantly expressed as protein products, the dominant expression of the aberrant transcripts at the expense of the wild-type receptor at transcription would have the end result of reducing levels of functional receptor. These variants are often dismissed as being a result of leaky transcription, although some of these transcripts are highly expressed such as the aberrant transcripts of CRHR2 ␤ (18) and CRHR2 ␣ (58). The tissue specificity of these transcripts needs to be determined if a correlation between expression of aberrant transcripts and functional receptor transcripts is to be linked to a regulatory splicing event. These aberrant transcripts are all too often ignored, and it is clear that more work is necessary particularly in the area of physiological and pathophysiological relevance, especially as there are several reports linking splice variants with disease (59) (60) (61) .
The arrangement and function of the 5Ј end of the CRHR2 gene with multiple promoters regulating receptor subtype expression will provide valuable information for further functional studies and interpreting past analyses. We can now determine which tissues and cell lines contain functional receptor and not confuse them with splice variants. This is essential for stimulation studies that examine expression of a specific receptor subtype and its relation to the expression of specific ligands for CRH receptors. The characterization of the three promoters can now direct functional studies on the individual receptor subtypes. Little is known about the function of the CRHR2 ␥ , although putative binding elements suggest an important role in the pituitary and regulation by glucocorticoids and estrogen. The CRHR2 ␤ has been shown to be expressed in both the human and rodent cardiovascular system and, in the rodent at least, is regulated by glucocorticoids (42, 62) . Interestingly, the human CRHR2 ␤ promoter contains putative binding elements for myogenic binding factors, which are highly conserved between species, but none for the GR. CRHR2 expression in the heart differs between human and rodents where in humans CRHR2 ␣ is predominant, in rodents it is the CRHR2 ␤ subtype. CRHR2 ␣ also contains a putative myogenic binding element, which is not conserved in rodents and contains binding elements for the GR; this may well explain the discrepancies between species. Identification of the CRHR2 promoters will now allow a more focused approach to subtype regulation by mutational analysis of specific elements and direct novel stimulation studies such as a possible role of retinoic acid in CRH receptor regulation.
All the features of the CRHR2 gene are common throughout group II GPCRs, such as alternate splicing, multiple promoters, truncated receptors, alternate 5Ј-UTR, etc. It is evident that a common mode of transcriptional control has evolved, involving both promoter and splicing regulation to control the expression of functional and variant receptors. The evolutionary relevance of multiple promoters and alternate splicing serve as a molecular tool to introduce more diversity into gene expression. The fact that group II GPCRs have multiple coding exons in comparison to other GPCR family members may be due to them being generated as an alternative to gene duplication during evolution. The increasing complexity seen within the subfamily seems to have evolved by divergence from a simpler regulated gene with increasing complexity of the organism. The CRH receptors are a good example, CRHR2 appears to have diverged from CRHR1 by duplication and then by increasing complexity to produce three subtypes with different pharmacology and differential expression. CRHR2 ␣ is present in amphibians, whereas in rodents a second variant CRHR2 ␤ is also present and in primates a third variant CRHR2 ␥ . As more members of the group II GPCR family are extensively studied the trend for increasing complexity using multiple promoters and alternate splicing may become more apparent.
MATERIALS AND METHODS
Isolation of Genomic Clones by Genomic Library Screening and Southern Blotting
A human placental cosmid library was purchased from CLONTECH Laboratories, Inc. (Oxford, UK) . Approximately 0.5 ϫ 10 6 plaques were screened using the plaque hybridization method with a 32 P-labeled DNA probe containing nucleotides 1-97 of CRHR2 ␣ (U34587). Positive phage clones were isolated and analyzed by Southern blot with 32 P-end-labeled oligonucleotides specific to CRHR2 ␤ , CRHR2 ␥ , and CRHR2 ␣ . Subclones were sequenced using an ABI 373A (PE Applied Biosystems, Warrington, UK) automated fluorescent sequencer.
5-RACE
To determine the 5Ј end of the CRHR2 subtypes, 5Ј-RACE was performed using Marathon Ready human hippocampus cDNA (CLONTECH Laboratories, Inc.) according to the manufacturer's instructions. Primary PCR was carried out using a gene specific primer (CRHR2 ␤ : 5Ј-GAGGAGGTGTGGGACG-TAGAGGAG, CRHR2 ␥ : 5Ј-GCAGAAGAGCTGAGGAAAGC-CCAGGTC, CRHR2 ␣ : 5Ј-CAGCCGTCCAAGAGCAGCTCT-TCAG) and the anchor primer AP1. Secondary PCR was carried out using a nested gene specific primer (CRHR2 ␤ : 5Ј-GGTATTCTCCACCCACTTCTTCCAC, CRHR2 ␥ : 5Ј-AAAG-CCCAGGTCCCTGTCTTCAGGC, CRHR2 ␣ : 5Ј-CTTCAGCCA-GCGCCAGGCTGCAGTTG) and the anchor primer AP2 with 2.0 l of primary PCR product as template. The PCR products were analyzed on a 1% agarose gel, extracted and subcloned into the pGEM-T vector (Promega Corp., Southampton, UK) for sequencing.
Luciferase Plasmid Construction
Flanking sequences 5Ј to the translational start site of ␤, ␥, and ␣ receptor genes were PCR amplified from genomic 
CTGTACCCGCAGCTCCGT p-␣Reverse GGAGTGGACGCGAGAGTG DNA, cloned into the pGL-3 basic vector (Promega Corp.) and sequence verified. Primers used for this PCR had a 5Ј KpnI restriction site in the 5Ј primer and a XhoI or BglII site in the 3Ј primer to facilitate cloning. Constructs were designed using the primers described in Table 2 .
Amplification of CRHR2 ␣ by PCR
PCR was performed using 20 ng of human brain cDNA (CLONTECH Laboratories, Inc.) with 0.5 M of each primer, forward primer ␣-207: 5Ј-CACTCGGCGGCTCCTCTC-3Ј, reverse primer IS1 5Ј-TAGGAGTAGGGACCCTCGG-3Ј, which hybridizes with the end of exon ␣1 and the start of exon 2, this prevents amplification from genomic template. The PCR mixture contained 1.3 M Betaine (Sigma, Gillingham, UK) and 1.3% dimethylsulfoxide, after 5 min at 95 C, 1 U of KlenTaq (Sigma) was added. PCR parameters: 94 C for 30 sec, 66 C for 30 sec, 72 C for 30 sec, 37 cycles, and a final extension at 72 C for 5 min. Products were analyzed by electrophoreses on a 1.5% agarose gel.
Transient Transfection and Reporter Gene Analysis
Human cell lines (myometrium primary myocytes, A431 skin epithelial, A549 lung epithelial, HEK293 kidney epithelial, MCF7 mammary gland epithelial) were seeded in six-well plates and cultured according to the American Type Culture Collection (Manassas, VA) recommendations until they were around 60% confluent. The cells were transfected with 1 g of plasmid DNA using Lipofectamine Plus (Life Technologies, Inc., Paisley, UK) in 1 ml of serum-free medium Optimem (Life Technologies, Inc.) for 3 h. All plasmid constructs were cotransfected with 1 g of the pRL-TK vector (Promega Corp.) to determine the transfection efficiency. Medium was replaced with 2 ml of fresh culture medium 3 h after transfection and cells were grown until 90% confluent. Cell extracts were prepared 24-36 h after transfection and assayed using a dual-luciferase reporter assay system (Promega Corp.). Luciferase activity was measured for 10 sec using a Luminoskan RS luminometer (Labsystems, Helsinki, Finland).
Database Sequence Analysis
Gene structure and exon mapping was determined using the DNA Star SeqMan tool, comparative promoter analysis using TRES and sequence alignments were performed using Multalign. The Transfac database was searched using AliBaba 2.1 for promoter elements and transcription start site prediction was determined using the 5Ј flanking sequence from the ATG start codon with NNPP (63), TSSG (64) , and TSSW (65) programs.
